1. Patients with advanced malignancies, either refractory to standard therapy or for which no effective standard therapy that increases survival for > 3 months is available, unless the drugs in the protocol are part of the standard of care for a specific diagnosis.Predominant hepatic metastasis is defined as at least 50% of the total tumor burden involving the liver. For patients who are enrolled into the arm of mFOLFOX6 plus Bevacizumab, they must have metastatic colorectal cancer with predominant hepatic metastases.For patients who are enrolled into the arm of DAT, they must have predominant hepatic metastases harboring an aberrant PI3K pathway detected in a CLIA-certified laboratory or with the tumor type that showed meaningfully clinical benefit to the treatment with DAT.